GlassScriptPhysician profile
Rudy A Ramirez
NPI 1417654187
$363.51
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $203 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.68 | 2023-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $48.18 | 2025 | |
| Antares Pharma, INC. | $47.10 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $37.00 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $25.23 | 2025 | Pediarix, Bexsero |
| Virtus Pharmaceuticals LLC | $24.98 | 2025 | Levorphanol Tartrate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.96 | 2023 | |
| Halozyme INC | $21.21 | 2023 | |
| Merck Sharp & Dohme LLC | $20.17 | 2023 | M-M-R II, Rotateq, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $16.18 | 2023 | Rexulti |
| Novo Nordisk INC | $16.10 | 2023 | Rybelsus |
| Abbvie INC. | $15.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudy Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.